Johnson & Johnson
Latest statistics and disclosures from Johnson & Johnson's latest quarterly 13F-HR filing:
- Top 5 stock holdings are PTGX, NBTX, MGTX, RAPP, CVRX, and represent 81.34% of Johnson & Johnson's stock portfolio.
- Added to shares of these 2 stocks: Vor Biopharma, LYEL.
- Started 2 new stock positions in Vor Biopharma, LYEL.
- Reduced shares in these 3 stocks: RAPP (-$21M), VOR, Lyell Immunopharma.
- Sold out of its positions in Lyell Immunopharma, VOR.
- Johnson & Johnson was a net seller of stock by $-19M.
- Johnson & Johnson has $504M in assets under management (AUM), dropping by 50.76%.
- Central Index Key (CIK): 0000200406
Tip: Access up to 7 years of quarterly data
Positions held by Johnson & Johnson consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Johnson & Johnson
Johnson & Johnson holds 20 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Protagonist Therapeutics (PTGX) | 32.3 | $163M | 2.4M | 66.43 |
|
|
| Nanobiotix Sponsored Ads (NBTX) | 21.1 | $106M | 5.6M | 18.89 |
|
|
| Meiragtx Holdings (MGTX) | 10.9 | $55M | 6.6M | 8.23 |
|
|
| Rapport Therapeutics (RAPP) | 10.5 | $53M | -28% | 1.8M | 29.70 |
|
| CVRX (CVRX) | 6.6 | $33M | 4.1M | 8.07 |
|
|
| Legend Biotech Corporation Sponsored Ads (LEGN) | 5.3 | $27M | 815k | 32.61 |
|
|
| Contineum Therapeutics Cl A (CTNM) | 4.6 | $23M | 2.0M | 11.75 |
|
|
| Procept Biorobotics Corp (PRCT) | 2.5 | $13M | 358k | 35.69 |
|
|
| Xencor (XNCR) | 1.7 | $8.8M | 748k | 11.73 |
|
|
| Arrowhead Pharmaceuticals (ARWR) | 1.7 | $8.5M | 248k | 34.49 |
|
|
| Fate Therapeutics (FATE) | 0.8 | $4.3M | 3.4M | 1.26 |
|
|
| Neumora Therapeutics (NMRA) | 0.7 | $3.4M | 1.8M | 1.82 |
|
|
| Vor Biopharma | 0.5 | $2.6M | NEW | 54k | 48.72 |
|
| Rallybio Corp (RLYB) | 0.4 | $1.8M | 3.6M | 0.50 |
|
|
| Lyell Immunopharma (LYEL) | 0.1 | $669k | NEW | 41k | 16.24 |
|
| Nano-X Imaging Ord Shs (NNOX) | 0.1 | $588k | 159k | 3.70 |
|
|
| D Fluidigm Corp Del (LAB) | 0.1 | $406k | 312k | 1.30 |
|
|
| Adicet Bio (ACET) | 0.1 | $295k | 365k | 0.81 |
|
|
| Chardan Healthcare Acqu- Ord | 0.0 | $51k | 97k | 0.53 |
|
|
| Senseonics Hldgs (SENS) | 0.0 | $24k | 55k | 0.44 |
|
Past Filings by Johnson & Johnson
SEC 13F filings are viewable for Johnson & Johnson going back to 2021
- Johnson & Johnson 2025 Q3 filed Nov. 13, 2025
- Johnson & Johnson 2025 Q2 filed July 22, 2025
- Johnson & Johnson 2025 Q1 filed May 7, 2025
- Johnson & Johnson 2024 Q4 filed Feb. 13, 2025
- Johnson & Johnson 2024 Q3 filed Nov. 13, 2024
- Johnson & Johnson 2024 Q2 filed Aug. 9, 2024
- Johnson & Johnson 2024 Q1 filed May 10, 2024
- Johnson & Johnson 2023 Q3 filed Nov. 9, 2023
- Johnson & Johnson 2023 Q2 filed Aug. 2, 2023
- Johnson & Johnson 2023 Q1 filed May 11, 2023
- Johnson & Johnson 2022 Q4 filed Feb. 9, 2023
- Johnson & Johnson 2022 Q3 filed Nov. 10, 2022
- Johnson & Johnson 2022 Q2 filed Aug. 10, 2022
- Johnson & Johnson 2022 Q1 filed May 9, 2022
- Johnson & Johnson 2021 Q4 filed Feb. 14, 2022
- Johnson & Johnson 2021 Q3 restated filed Nov. 16, 2021